70-year-old advanced lung cancer can live for a few years with targeted drugs
For patients with late-stage lung cancer who took targeted drugs, the time from the start of treatment to the progression of the disease or the patient's death was 9.2 to 18.9 months. The general overall survival period was 21.6 to 36 months. There was also data that showed that the average survival time was about three years, but this was only a rough range. The specific situation needs to be determined based on the patient's physical condition (such as whether the patient has cardiovascular diseases, chronic rheumatism, liver diseases, and other basic diseases), the effect of targeted therapy, the patient's attitude and degree of cooperation with the treatment, as well as the support, care, and economic investment of the family members. There are individual differences. Some studies had shown that after comprehensive treatment, the 2-year survival rate of stage IUA lung cancer patients was 23%, the 5-year survival rate was 10%, and the mean survival time was 11.5 months. For stage IUA lung cancer patients who had multiple metastasies, the 2-year survival rate was 10%, and the mean survival time was 6 months. In addition, with the deepening of targeted drug research, more efficient targeted drugs could effectively prolong the survival of patients with advanced lung cancer. Read more exciting novels for free
What is the survival rate of targeted drugs in the treatment of advanced lung cancer?
There was a large individual difference in the survival rate of patients with advanced lung cancer after taking targeted drugs. The time from the start of treatment to disease progression or death was 9.2 - 18.9 months, and the general overall survival period was 21.6 - 36 months. Some studies had shown that the average survival time for late-stage lung cancer patients with targeted drugs was about three years, but there were also cases where it was as short as one or two years and as long as ten years. According to the data, after comprehensive treatment, the 2-year survival rate of stage IUA lung cancer patients was 23%, the 5-year survival rate was 10%, and the medium survival time was 11.5 months. For stage IUA lung cancer patients who had multiple metastasies, the 2-year survival rate was 10%, and the medium survival time was 6 months. In addition, in some studies, the 1-year, 2-year, 3-year, 4-year, and 5-year overall survival rates of the control group (first-line therapy with a combination of a combination The patient's physical condition, the effect of the targeted therapy, whether the attitude was positive, the degree of cooperation with the treatment, whether the patient had underlying diseases, and the support, care, and financial investment of the family would all affect the survival rate. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
Is it always effective to take targeted drugs for lung cancer?
The effect of targeted drugs on lung cancer patients was not very good. Target drugs could not cure lung cancer. Although they could prolong survival time, they could not always be effective. There were very few driver mutations in lung cancer, so there were relatively few targeted drugs that could be used. When using targeted drugs, it was necessary to find the target of lung cancer and could not be used blindly. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
How long will it take for targeted drugs to be effective for lung cancer?
Patients with lung cancer usually took targeted drugs for ten days, no more than forty days, and the effect would take effect in two to three days. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
How long do you take targeted drugs for lung cancer?
The time taken for targeted treatment of lung cancer needed to be considered from both the patient's own condition and the progression of the disease. For patients with middle-stage lung cancer, it is recommended to take the first-generation targeted drug for 1.5 - 2 years or the third-generation targeted drug for 3 years. For patients with advanced lung cancer, as long as the targeted drug was effective, it was recommended to take it until the disease progressed. If drug resistance appeared, the targeted drug would need to be replaced. However, it should be noted that the premise of using targeted drugs was that the patient must have a clear target for treatment in the body, and there must be a specific drug targeting the target before targeted drug therapy could be carried out. Less than 20% of lung cancer patients could find targeted drugs. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
Does lung cancer have targeted drugs that need to be taken all the time?
Whether or not targeted drugs for lung cancer needed to be taken all the time could not be said to be the same. On the one hand, targeted drugs may face the problem of drug resistance in cancer cells during treatment. Due to the rapid evolution of cancer cells, new genetic mutations may occur during the targeted drug treatment to avoid the targeted drug attack, resulting in drug resistance in the body. Once this happens, the targeted drug may not be able to continue to effectively suppress tumor growth. At this time, it may be necessary to change the treatment plan, such as switching to other targeted drugs or changing to chemotherapy. On the other hand, if the patient had a good response to the targeted drug and did not have any serious adverse reactions or drug resistance, from the perspective of continuous suppression of tumor cell growth and prevention of cancer relapse and migration, it might be necessary to continue taking the targeted drug to maintain the treatment effect. At the same time, factors such as the patient's actual disease progression and overall physical condition would also affect the duration of the targeted drug's use. The specifics should be determined according to the diagnosis of a professional doctor. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
Is an 85-year-old man's late-stage lung cancer targeted drug effective?
Advanced lung cancer could be treated with targeted therapy, which was a very important method in the treatment of lung cancer. However, targeted therapy required a specific target. It was a precise treatment method. The appropriate targeted drug had to be selected according to the different pathological types of lung cancer and the different gene mutation characteristics. For an 85-year-old patient with advanced lung cancer, if there was a suitable target, the targeted drug was effective. For example, in patients with lung cancer with advanced egfr-mutation, the effective rate of oral egfr-small-molecular Tyrosin Kinase Inhibition targeted drugs could reach 70%. The efficacy was better than chemotherapy and the side effects were significantly lower than chemotherapy. Most patients could tolerate it, even in elderly patients. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
What are the names of the drugs used to treat advanced small cell lung cancer?
The drugs used to treat late-stage small cell lung cancer included TaiShengQi (atilibizab), temoziromide, eloposide, irinotecan, platinum, and topographic. Among them, TaiShengQi (atilibizab) was an immune targeting drug; temozuorm could be used as a recommended drug for advanced small cell lung cancer, which had a good effect on the treatment of brain metastasies; Etoposide or irinotecan could be combined with platinum as the first-line chemotherapy scheme, and if the first-line scheme was resistant to the drug, the second line scheme could be selected to be the second line scheme. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
Is there reimbursement for Changde lung cancer targeted drug?
Based on the information provided so far, it was impossible to determine whether Changde's targeted lung cancer drug was eligible for reimbursement. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
There are several types of breast cancer targeted drugs
There were mainly the following types of breast cancer targeted drugs: 1. Anti-neoplastic targeted drugs: There are intravenous preparations and oral drugs, but the effect in the treatment of breast cancer is not ideal. For example, bevacidol (Avastin) will be considered in some cases. 2. Anti-Her- 2 targeted drugs: targeted at HER - 2 positive patients, it is the most important targeted drug for breast cancer, mainly including trastuzumab (Herceptin), pertubizab, dm- 1, lapatini, etc. The prerequisite for use was that the patient was positive for HER - 2 (+++ in the immune tissue test). If the immune tissue test was ++, the patient would need to undergo a further FISH test. The patient could only be used if the FISH test was positive. If the immune tissue test was + or-, the patient could not be used. 3. A targeted drug for patients with fetal mutations in the Brca lineage: The main drug is olaparib, which is used to treat patients with metastasizing breast cancer who have harmful or suspected harmful mutations in the Brca lineage and who are negative for the human embryonic growth factor receptor 2 (HEL2). 4. Immune therapy (in a sense, it was also a targeted drug): Anti-PD- 1/PD-L1 Monoclone Antibodies, which essentially relieved immune suppression and activated immune cells to kill cancer cells. 5. mTO inhibition drugs, such as everolimus and sirolimus, can inhibit the activation of the mTO signaling pathway, thereby suppressing the growth and metabolism of tumor cells. 6. Other targeted therapy drugs, such as Parp inhibition drugs, CD 4/6 inhibition drugs, etc. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
Is it useful to take targeted drugs for esophagus cancer metastasizing?
At present, a variety of targeted drugs were available for the treatment of esophagus cancer, including new small molecules multi-target Tyrosin Kinase Inhibition, drugs that targeted HEL2, cetuxed that targeted the egFr target, and bevacizumb that targeted the veg-like growth factor target, etc. There was also a combination of PD1 - 1 inhibition and targeted HEL2 for the treatment of cancer at the gastric-esophagus junction. Chinese studies have shown that as a new small-molecular multi-target Tyrosinase Kinase Inhibition, anlotinib and apitini have a certain effect in the treatment of esophagus cancer. The combination therapy of trastuzumab-targeted to HEL2 and PD1 inhibition drugs (such as pembrolizumab) combined with chemotherapy can be used as the first-line treatment for cancer of the gastroesophagus junction, advanced gastric cancer with HEL2 positive, and esophagus cancer. In the second-line treatment of China guidelines for the treatment of esophagus cancer, level II recommendations were given to anlotinib (Class 2A) and apitini (Class 3). However, there were no phase III clinical trials to prove that molecular targeted drugs could prolong the survival of patients with esophagus cancer. The effect of targeted therapy needed further study. In general, molecular targeted therapy had a certain clinical value for the treatment of patients with esophagus cancer, including those with metastasizing, but it still needed further in-depth research. These drugs must be used under the guidance of a professional doctor. It is not recommended for patients to buy and take them themselves to avoid serious adverse reactions. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>